US · LYRA
Lyra Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Watertown, MA 02472
- Website
- lyratherapeutics.com
Price · as of 2024-12-31
—
Market cap 1.79M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.39 | — |
| Intrinsic Value(DCF) | $3.84 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $699.00 | ||||
| 2021 | $217.00 | $0.00 | $0.00 | ||
| 2022 | $100.00 | $89.33 | $0.69 | $0.00 | $0.00 |
| 2023 | $265.50 | $126.52 | $0.37 | $0.00 | $0.00 |
| 2024 | $9.60 | $25.39 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Lyra Therapeutics, Inc.'s (LYRA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.39
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.84
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LYRA | Lyra Therapeutics, Inc. | $1.01 | 1.79M | +2,414% | +280% | — | — | -6.69 | 53.92 | 407.49 | -10.27 | -49.59 | 53.92 | 100.00% | -6280.83% | -6090.94% | -184.99% | -1017.13% | -89.43% | 2.97 | — | 3.41 | 3.21 | 0.10 | 1349.00% | -154.00% | 1243.00% | -11.57% | -5.54 | -763.78% | 0.00% | 0.00% | 1.72% | -6.42 | -8.55 | 403.45 | -5.91 |
| APVO | Aptevo Therapeutics Inc. | $7.32 | 6.85M | — | — | — | — | -0.03 | 0.15 | — | 0.14 | — | 0.15 | 0.00% | — | — | -284.28% | -3555.20% | -119.36% | 0.97 | — | 1.72 | 1.40 | 0.17 | -9623.00% | — | 10277.00% | -3391.13% | -3.83 | -3437.14% | 0.00% | 0.00% | 0.00% | 0.14 | 0.14 | — | -27.06 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| CDIO | Cardio Diagnostics Holdin… | $6.55 | 11.96M | +576% | -17% | — | — | -43.50 | 38.15 | 10451.97 | -44.24 | — | 41.20 | 100.00% | -23977.86% | -24028.24% | -133.96% | -296.88% | -111.20% | 0.10 | -448.81 | 13.92 | 12.42 | 0.85 | -5303.00% | 10445.00% | -1653.00% | -1.48% | -7.90 | -191.54% | 0.00% | 0.00% | 1.87% | -42.77 | -66.29 | 10255.42 | 202.22 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLRB | Cellectar Biosciences, In… | $3.25 | 10.36M | — | — | — | — | -0.26 | 0.82 | — | 0.22 | — | 0.82 | 0.00% | — | — | -17221.69% | 330.97% | -237.45% | 0.03 | — | 2.58 | 2.48 | 0.44 | -6010.00% | — | 4346.00% | -406.92% | -5.07 | 304.82% | 0.00% | 0.00% | 117.61% | 0.21 | 0.23 | — | -18.97 |
| GLTO | Galecto, Inc. | $29.58 | 47.25M | — | — | — | — | -0.22 | 0.30 | — | 0.45 | — | 0.30 | 0.00% | — | — | -89.03% | -3844.56% | -77.45% | 0.00 | — | 14.07 | 12.58 | 0.67 | -4864.00% | — | -4955.00% | -396.40% | -15.56 | -3216.41% | 0.00% | 0.00% | 0.00% | 0.42 | 0.50 | — | -23.70 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| INAB | IN8bio, Inc. | $1.70 | 7.88M | — | — | — | — | -13.04 | 27.41 | — | -14.50 | — | 27.41 | 0.00% | — | — | -154.44% | -359.44% | -111.38% | 0.35 | — | 4.08 | 3.61 | 0.23 | -4300.00% | — | 131.00% | -6.11% | -7.83 | -286.41% | 0.00% | 0.00% | 0.00% | -12.84 | -16.11 | — | 24.43 |
| RNAZ | TransCode Therapeutics, I… | $9.61 | 8.81M | — | — | — | — | -0.93 | -7.75 | — | -0.61 | — | -7.75 | 0.00% | — | — | 8866.96% | 369.89% | -268.85% | -0.02 | -584.07 | 2.56 | 2.10 | 0.36 | -9864.00% | — | -2624.00% | -85.33% | -4.81 | 315.50% | 0.00% | 0.00% | 22.07% | -0.63 | -0.74 | — | -17.50 |
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
- CEO
- Carmichael S. Roberts Jr.
- Employees
- 30
- Beta
- -0.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.84 ÷ —) − 1 = — (DCF, example).